NextCure, Inc.
NXTC
$9.63
-$0.01-0.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.09% | 4.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 134.83% | -6.69% | |||
| Operating Income | -134.83% | 6.69% | |||
| Income Before Tax | -144.24% | 5.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -144.24% | 5.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -144.24% | 5.40% | |||
| EBIT | -134.83% | 6.69% | |||
| EBITDA | -143.06% | 6.90% | |||
| EPS Basic | -140.04% | 5.40% | |||
| Normalized Basic EPS | -140.04% | 5.40% | |||
| EPS Diluted | -140.04% | 5.40% | |||
| Normalized Diluted EPS | -140.04% | 5.40% | |||
| Average Basic Shares Outstanding | 1.75% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.75% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||